Hormone Receptor Positive HER-2 Negative Breast Cancer Clinical Trial
Official title:
A Randomized, Open-label, Single-center, Phase III Trial Comparing Docetaxel Plus Carboplatin (TCb) Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel (EC-T) Regimen as Adjuvant Chemotherapy in Patients With LN≥4 Estrogen Receptor Positive and Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Breast Cancer
This study will evaluate the efficacy and safety of docetaxel plus carboplatin (TCb) regimen compared with conventional chemotherapy regimen (epirubicin plus cyclophosphamide followed by docetaxel, EC-T) regimen as adjuvant chemotherapy in patients with early-stage high-risk estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02692755 -
Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06201234 -
Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05573126 -
Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06257264 -
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
|
Phase 1 | |
Recruiting |
NCT05608252 -
VS-6766+Abema+Fulv in Met HR+/HER- BC
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06369285 -
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT06120283 -
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05878314 -
Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer
|